

DIVI'S LABORATORIES LIMITED

UN-AUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH SEPTEMBER, 2008

(Rs.in Lakhs)

	Particulars	STANDALONE					CONSOLIDATED				
		Quarter ended 30.09.2008	Quarter Ended 30.09.2007	Period ended 30.09.2008	Period ended 30.09.2007	Year ended 31.03.2008	Quarter ended 30.09.2008	Quarter ended 30.09.2007	Period ended 30.09.2008	Period ended 30.09.2007	Year ended 31.03.2008
		Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)
1	(a) Net Sales/Income from operations (Net of Excise Duty)	33122	24251	59729	47058	103319	33047	24384	59405	47056	103283
	(b) Other Operating Income	258	160	609	440	1174	258	159	609	440	1231
	<u>Total Income</u>	33380	24411	60338	47498	104493	33305	24543	60014	47496	104514
2	<u>Expenditure:</u>										
	a. (Increase) / Decrease in Stock-in-Trade and Work-in-Progress	(4020)	(2118)	(6821)	(2741)	(3219)	(4275)	(2223)	(7636)	(2903)	(3569)
	b. Consumption of Raw Material	14898	10883	27143	21596	44388	14897	10977	27259	21635	44528
	c. Purchase of Traded Goods	0	0	0	0	0	0	0	0	0	0
	d. Staff Cost	1597	1212	3079	2360	5054	1698	1340	3277	2575	5419
	e. Depreciation	1193	782	2266	1643	3565	1194	782	2268	1644	3568
	f. Other Expenditure										
	- Manufacturing Expenses	1807	1659	3706	3075	6451	1807	1770	3816	3187	6561
	- Other expenses	2795	2152	5596	3841	8954	3129	2181	6154	3953	9386
	g. Total	18270	14570	34969	29774	65193	18450	14827	35138	30091	65893
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	15110	9841	25369	17724	39300	14855	9716	24876	17405	38621
4	Other Income	258	32	426	58	187	242	23	396	41	148
5	Profit before Interest & Exceptional Items (3+4)	15368	9873	25795	17782	39487	15097	9739	25272	17446	38769
6	Interest/Finance Charges	183	315	379	652	1018	184	316	380	653	1019
7	Profit after Interest but before Exceptional Items (5-6)	15185	9558	25416	17130	38469	14913	9423	24892	16793	37750
8	Exceptional items	0	0	0	0	0	0	0	0	0	0
9	<u>Profit from ordinary activities before Tax (7+8)</u>	15185	9558	25416	17130	38469	14913	9423	24892	16793	37750

10	Tax Expense											
	- Current Tax	1272	1004	2017	1851	3834		1272	1004	2017	1851	3834
	- MAT Credit Entitlements	(164)	(999)	(495)	(1361)	(1930)		(164)	(999)	(495)	(1361)	(1930)
	- Deferred Tax	304	423	466	778	1177		261	316	386	708	1054
	- Fringe Benefit Tax	5	5	12	9	32		5	5	12	9	32
11	<u>Net Profit from ordinary activities after Tax: (9-10)</u>	13768	9125	23416	15853	35356		13539	9097	22972	15586	34760
12	Extra-ordinary items (net of tax expense)	0	0	0	0	0		0	0	0	0	0
13	Net Profit (+)/Loss(-) for the period (11-12)	13768	9125	23416	15853	35356		13539	9097	22972	15586	34760
14	Paid-up Equity Share Capital (Face Value: Rs.2 each)	1294	1291	1294	1291	1291		1294	1291	1294	1291	1291
15	Reserves excluding revaluation reserves					86107						84849
16	Earnings per Share											
a)	Basic Earnings Per Share before extra-ordinary items Rs.	21.28	14.13	36.19	24.56	54.77		20.92	14.09	35.51	24.14	53.84
	Diluted Earnings Per Share before extra-ordinary items Rs.	21.06	13.97	35.81	24.28	54.14		20.71	13.93	35.13	23.87	53.23
b)	Basic Earnings Per Share after extra-ordinary items Rs.	21.28	14.13	36.19	24.56	54.77		20.92	14.09	35.51	24.14	53.84
	Diluted Earnings Per Share after extra-ordinary items Rs.	21.06	13.97	35.81	24.28	54.14		20.71	13.93	35.13	23.87	53.23
17	Public shareholding:											
	- No. of shares	30139825	29992600	30139825	29992600	29972600		30139825	29992600	30139825	29992600	29972600
	- % of shareholding	46.57%	46.46%	46.57%	46.46%	46.43%		46.57%	46.46%	46.57%	46.46%	46.43%

NOTES:

1. The above results for the Quarter ended 30th September 2008, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 29th October, 2008.
2. The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates. Accordingly there are no reportable segments as per Accounting Standard 17 on Segment Reporting notified under the Companies Act, 1956.
3. The consolidated results include the unaudited results of the subsidiaries Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG
4. The figures for the previous year/period have been reclassified/regrouped, wherever necessary.
5. During the current quarter, the company has allotted 51,175 equity shares of Rs.2/- each to the employees on exercise of their stock options.
6. Details of Investor complaints pursuant to Clause 41 of the Listing Agreement for the quarter ended 30.09.2008:
Opening: Nil, Received during the Quarter: 20, Resolved: 20, Closing: Nil

for Divi's Laboratories Limited

Place: Hyderabad
Date: 29-10-2008

Dr. Murali K. Divi
Chairman & Managing Director